Cancer Treatment-Related Cardiotoxicity


Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prevent recurrence, prolong life and provide cure. However, many of these treatments can cause devastating cardiovascular complications for the patient such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. Developing and understanding optimal prevention, early detection and treatment strategies for cardiotoxicity related to anticancer treatment is a critical aspect of cancer patient care, and may have a significant impact on the overall prognosis and survival of cancer patients. These important clinical events are a significant challenge for both cardiologists and oncologists and will continue to be in the future, particularly due to an increasing aging population of patients with cancer and the introduction of many new targeted cancer therapies.

Efforts to identify individual toxicity risks and prevention strategies support the National Cancer Insitute's (NCI) goal of reducing the burden of cancer diagnoses and treatment outcomes. NCI's vision for the future includes precision medicine that not only provides effective therapy for eradicating disease, but also maintains the function of normal tissues, thus decreasing the burden of cancer throughout the survivorship spectrum.

Return to Top

Funding Opportunities

NCI-sponsored Funding Opportunity Announcements (FOAs) related to cancer treatment-related cardiotoxicity research include:

  • Improving Outcomes in Cancer Treatment-Related Cardiotoxicity - expires January 8, 2022

EGRP joins with other NCI Divisions, Offices, and Centers and other Institutes and Centers at the National Institutes of Health (NIH) to fund grant applications submitted in response to FOAs. View the full list of EGRP FOAs.

Return to Top

Workshops, Conferences, and Webinars

Return to Top


For general questions about cancer treatment-related cardiotoxicity, contact:

  • Nonniekaye F. Shelburne, C.R.N.P., M.S., A.O.C.N. Program Director, Clinical and Translational Epidemiology Branch

Return to Top